Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 3/20 | 0.43 |
| ▸ | FNTB | P49356 | 3/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL9051836 | 0.90 | SLC7A5 (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5159598 | 0.87 | SLC7A5 (0.50) | SLC7A5 | |
| SCHEMBL14658220 | 0.87 | ALPI (0.45) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL28820471 | 0.84 | SLC7A5 (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL288607 | 0.84 | SLC7A5 (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8835936 | 0.84 | SLC7A5 (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3495948 | 0.84 | ALPI (0.44) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dl-Phenylalanine SCHEMBL464776 | 0.84 | SLC7A5 (0.69) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dl-Phenylalanine SCHEMBL29503517 | 0.84 | SLC7A5 (0.69) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Phenylalanine SCHEMBL28231547 | 0.84 | SLC7A5 (0.69) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277098-A1 | NOVEL AND USEFUL EDIBLE SALT AND METHODS OF USE AND PRODUCTION THEREOF | E.k.salt Ltd. (IL) | 2018-02-07 | — | — | EP | claimed |
| WO-2016157178-A1 | NOVEL AND USEFUL EDIBLE SALT AND METHODS OF USE AND PRODUCTION THEREOF | E.K.SALT LTD. (IL) | 2016-10-06 | — | — | WO | claimed |
| US-9181224-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2015-11-10 | — | — | US | claimed |
| WO-2006031844-A2 | TREATING THE CAUSE OF BACK PAIN WITH TRACTION WITHIN HYPERBARIC CHAMBER | YEUNG JEFFREY E (US) | 2006-03-23 | — | — | WO | claimed |
| EP-1383793-A2 | INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS | DGI BioTechnologies, L.L.C. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2001072771-A2 | INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS | DGI BIOTECHNOLOGIES, L.L.C. (US) | 2001-10-04 | — | — | WO | claimed |
| US-5304658-A | Quinone derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-19 | — | — | US | claimed |
| CN-115389756-B | Detection kit for predicting risk of atrial fibrillation and application thereof | 首都医科大学附属北京安贞医院 | 2023-02-17 | — | — | CN | disclosed |
| CN-115389756-A | Detection kit for predicting risk of atrial fibrillation and application thereof | 首都医科大学附属北京安贞医院 | 2022-11-25 | — | — | CN | disclosed |
| US-11366100-B2 | P13K-MTORC1-S6K1 signaling pathway biomarkers predictive of anti-cancer responses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220145396-A1 | METHOD OF IDENTIFYING PATIENTS WITH BORTEZOMIB RESISTANT MULTIPLE MYELOMA AND OTHER BLOOD DISEASES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220135622-A1 | ANTIBACTERIAL PEPTIDES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3931205-A1 | ANTIBACTERIAL PEPTIDES AND METHODS OF USE | Genentech, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| CN-1339298-A | Compound traditional medicine with piperine for increasing biological utilization of paeoniflorin and its preparing method | TANG XIAOHAI (CN) | 2002-03-13 | — | — | CN | disclosed |
| US-6074848-A | AMINO ACID SEQUENCE; FOR ANTIPROLIFERATIVE AND WOUND HEALING AGENTS | CHIRON CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0763107-A1 | PANTROPIC NEUROTROPHIC FACTORS | GENENTECH, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033829-A1 | PANTROPIC NEUROTROPHIC FACTORS | GENENTECH, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| EP-0331404-A2 | Method for producing tropane alkaloid | SEITAIKINOU RIYOU KAGAKUHIN SHINSEIZOUGIJUTSU KENKYU KUMIAI (JP) | 1989-09-06 | — | — | EP | disclosed |
| US-4604286-A | Infusion solution for parenteral nutrition | DAIGO NUTRITIVE CHEMICALS, LTD. (JP) | 1986-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220145396-A1 | METHOD OF IDENTIFYING PATIENTS WITH BORTEZOMIB RESISTANT MULTIPLE MYELOMA AND OTHER BLOOD DISEASES | PSMB5, PSMB4, PSMD5 | ALPI 4250/4885PKM 3809/4885PTGS1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.